Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Januar 2024

Genmab — Januar 2024

Planlagt Fastgjort Låst Flyttet Genmab
1.2k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • S Offline
    S Offline
    Sukkeralf
    wrote on sidst redigeret af
    #1107

    Synes Jan sagde på ASH eller JP Morgan, at de i højere grad retter fokus mod development og holder lidt igen på research. Sikkert klogt med patentudløb på daratumumab for øje. Drømmer stadig om at GEN1042 kan noget særligt, men blev lidt nervøs da vi intet hørte i slutningen af 2023.

    1 Reply Last reply
    0
    • S Offline
      S Offline
      Sukkeralf
      wrote on sidst redigeret af
      #1108

      Må vist lige finde den præcise formulering i weekenden.

      1 Reply Last reply
      0
      • P Offline
        P Offline
        ProinvestorNEWS
        wrote on sidst redigeret af
        #1109

        NJ Stock: What to Consider Before Its Next Dividend Hike https://www.proinvestor.com/investornyt/1108802/jnj-stock-what-to-consider-before-its-next-dividend-hike

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #1110

          Perseus video https://www.youtube.com/watch?v=mpiSaMj0kFY

          1 Reply Last reply
          0
          • W Offline
            W Offline
            w
            wrote on sidst redigeret af
            #1111

            ØU https://ugebrev.dk/flashnews/teknisk-var-det-bunden-for-genmab-efter-en-lang-nedtur/

            1 Reply Last reply
            0
            • H Offline
              H Offline
              Hen
              wrote on sidst redigeret af
              #1112

              Låst artikel.
              "Vi har senest øget positionen i Genmab i ØUs portefølje, da der med de seneste meddelelser er taget en del risiko ud af aktien." Hvilke meddelelser er det, de sigter til?

              1 Reply Last reply
              0
              • H Offline
                H Offline
                Hen
                wrote on sidst redigeret af
                #1113

                Slet ingen med adgang til AU?

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #1114

                  I have not read the article, but i assume he means that there is no more uncertainty about the arbitrage -the (negative) outcome is now known, so that particular risk is now gone

                  1 Reply Last reply
                  0
                  • H Offline
                    H Offline
                    Hen
                    wrote on sidst redigeret af
                    #1115

                    Tak for svaret, EL.

                    1 Reply Last reply
                    0
                    • DarvinD Offline
                      DarvinD Offline
                      Darvin
                      wrote on sidst redigeret af
                      #1116

                      Godmorgen og enig JV 26.01 16.52

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #1117

                        All About TALVEY (talquetamab) - video https://www.youtube.com/watch?v=sUQnK-a4TvY

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #1118

                          'epcoritamabe' was also in approved in Brazil last dec
                          https://jornaldr1.com.br/anvisa-aprova-primeiro-anticorpo-biespecifico-para-tratar-tipo-agressivo-de-cancer-no-sangue/

                          1 Reply Last reply
                          0
                          • S Offline
                            S Offline
                            Sukkeralf
                            wrote on sidst redigeret af
                            #1119

                            Alligator Bio har succes med deres CD40 monoclonale antistof Mitazalimab, så lad os håbe Genmab kan toppe den:

                            1 Reply Last reply
                            0
                            • S Offline
                              S Offline
                              Sukkeralf
                              wrote on sidst redigeret af
                              #1120

                              Link Preview Image
                              Alligator Bioscience Announces Positive Mitazalimab OPTIMIZE-1 Phase 2 Results Meeting Primary Endpoint and Demonstrating Clinically Relevant Survival Benefits in 1st Line Pancreatic Cancer – Alligator Bioscience

                              Top-line readout demonstrates Objective Response Rate of 40.4%, meeting primary endpoint and confirming the benefit of mitazalimab in combin ...

                              favicon

                              (alligatorbioscience.se)

                              1 Reply Last reply
                              0
                              • nohopeN Offline
                                nohopeN Offline
                                nohope
                                wrote on sidst redigeret af
                                #1121

                                Skal kun stige yderligere 120 % for at jeg går i nul...

                                1 Reply Last reply
                                0
                                • nohopeN Offline
                                  nohopeN Offline
                                  nohope
                                  wrote on sidst redigeret af
                                  #1122

                                  -Efter den er steget 280 % på 3 mdr...

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #1123

                                    Genmab price target raised by $1 at H.C. Wainwright to$50, maintains buy

                                    1 Reply Last reply
                                    0
                                    • W Offline
                                      W Offline
                                      w
                                      wrote on sidst redigeret af
                                      #1124

                                      insane

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #1125

                                        too low...? 😉

                                        1 Reply Last reply
                                        0
                                        • G Offline
                                          G Offline
                                          gentogen
                                          wrote on sidst redigeret af
                                          #1126

                                          Most likely...

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper